EA201591047A1 - Новая фармацевтическая композиция - Google Patents

Новая фармацевтическая композиция

Info

Publication number
EA201591047A1
EA201591047A1 EA201591047A EA201591047A EA201591047A1 EA 201591047 A1 EA201591047 A1 EA 201591047A1 EA 201591047 A EA201591047 A EA 201591047A EA 201591047 A EA201591047 A EA 201591047A EA 201591047 A1 EA201591047 A1 EA 201591047A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new pharmaceutical
pharmaceutical composition
methods
dimethyl
iodophenylamino
Prior art date
Application number
EA201591047A
Other languages
English (en)
Other versions
EA028246B1 (ru
Inventor
Госсетт Кэмпбелл
Франциско Энрикес
Original Assignee
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ГЛЭКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201591047A1 publication Critical patent/EA201591047A1/ru
Publication of EA028246B1 publication Critical patent/EA028246B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Раскрыты новые фармацевтические составы, содержащие сольват N-{3-[3-циклопропил-5-(2-фтор-4-йодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]фенил}ацетамид-диметилсульфоксида, способы применения композиций в лечении и способы их получения.
EA201591047A 2012-11-30 2013-11-26 Фармацевтическая композиция EA028246B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731597P 2012-11-30 2012-11-30
US61/731,597 2012-11-30
PCT/US2013/071816 WO2014085371A1 (en) 2012-11-30 2013-11-26 Novel pharmaceutical composition

Publications (2)

Publication Number Publication Date
EA201591047A1 true EA201591047A1 (ru) 2015-11-30
EA028246B1 EA028246B1 (ru) 2017-10-31

Family

ID=50828398

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791411A EA201791411A1 (ru) 2012-11-30 2013-11-26 Новая фармацевтическая композиция
EA201591047A EA028246B1 (ru) 2012-11-30 2013-11-26 Фармацевтическая композиция

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201791411A EA201791411A1 (ru) 2012-11-30 2013-11-26 Новая фармацевтическая композиция

Country Status (29)

Country Link
US (2) US20150328320A1 (ru)
EP (2) EP3400933A1 (ru)
JP (1) JP6232443B2 (ru)
KR (1) KR102206432B1 (ru)
CN (2) CN104902876B (ru)
AR (1) AR093648A1 (ru)
AU (1) AU2013352369B2 (ru)
BR (1) BR112015012111A8 (ru)
CA (1) CA2891346A1 (ru)
CL (1) CL2015001459A1 (ru)
EA (2) EA201791411A1 (ru)
ES (1) ES2686730T3 (ru)
HK (1) HK1209047A1 (ru)
IL (3) IL266415B2 (ru)
IN (1) IN2015DN04094A (ru)
MA (1) MA38121A1 (ru)
MX (1) MX2015006867A (ru)
MY (1) MY170427A (ru)
NZ (1) NZ628395A (ru)
PE (1) PE20151024A1 (ru)
PH (1) PH12015501168A1 (ru)
PL (1) PL2925299T3 (ru)
PT (1) PT2925299T (ru)
SG (1) SG11201503688SA (ru)
TN (1) TN2015000198A1 (ru)
TW (2) TW201831187A (ru)
UY (1) UY35157A (ru)
WO (1) WO2014085371A1 (ru)
ZA (1) ZA201503346B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20200178569A1 (en) * 2016-04-29 2020-06-11 Alvin Kershman Method of Coating an Edible Thermoplastic Pet Chew
EP3545957A4 (en) * 2016-11-25 2020-07-22 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL PYRIDONE DERIVATIVE COMPOSITION AND PRODUCTION METHOD THEREFOR
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
BR112022007603A2 (pt) * 2019-10-22 2022-07-19 Chemistryrx Métodos para o tratar hiperplasia epidermica congênita
WO2023219465A1 (ko) * 2022-05-12 2023-11-16 주식회사 지뉴브 안정한 액상 제약 제제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
HUE027850T2 (en) * 2004-12-07 2016-11-28 Onyx Therapeutics Inc Preparation for proteasome inhibition
CN1872055A (zh) * 2005-06-01 2006-12-06 李�杰 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
HUE035181T2 (hu) * 2005-10-26 2018-05-02 Cydex Pharmaceuticals Inc Szulfoalkil-éter-ciklodextrin kompozíciók és eljárások elõállításukra
EP2121139B1 (en) * 2007-01-16 2012-10-10 BiPar Sciences, Inc. Formulations for cancer treatment
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101352419B (zh) * 2007-07-26 2010-08-11 天津药物研究院 一种醋溴茶碱无糖型颗粒剂及其制备方法
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
UA105064C2 (ru) * 2009-10-16 2014-04-10 Ґлаксосмітклайн Ллк КОМБИНАЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР МЭК И ИНГИБИТОР В-Raf
EP2638043B1 (en) * 2010-11-11 2017-06-07 Bayer Intellectual Property GmbH Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20130023531A1 (en) * 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
RU2568258C2 (ru) * 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
JO3068B1 (ar) * 2011-04-07 2017-03-15 Bayer Ip Gmbh إيميدازوبيريميدينات كمثبطات كيناز akt
CN102600132B (zh) * 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN102626394A (zh) * 2012-03-15 2012-08-08 合肥科大生物技术有限公司 一种精氨酸布洛芬颗粒剂及其制备方法

Also Published As

Publication number Publication date
CL2015001459A1 (es) 2015-12-18
IL238971A0 (en) 2015-07-30
PL2925299T3 (pl) 2018-11-30
ZA201503346B (en) 2016-01-27
IL238971B (en) 2019-05-30
IL266415B1 (en) 2023-11-01
US20170189408A1 (en) 2017-07-06
EP2925299A4 (en) 2016-06-29
TN2015000198A1 (en) 2016-10-03
EP2925299A1 (en) 2015-10-07
TW201831187A (zh) 2018-09-01
IL266415A (en) 2019-06-30
HK1209047A1 (en) 2016-03-24
AU2013352369A1 (en) 2015-05-28
ES2686730T3 (es) 2018-10-19
NZ628395A (en) 2016-10-28
PE20151024A1 (es) 2015-07-27
AU2013352369B2 (en) 2016-07-28
TW201434468A (zh) 2014-09-16
BR112015012111A8 (pt) 2018-01-23
JP2016501874A (ja) 2016-01-21
PT2925299T (pt) 2018-10-16
EA201791411A1 (ru) 2018-03-30
BR112015012111A2 (pt) 2017-07-11
PH12015501168A1 (en) 2015-08-10
EP2925299B1 (en) 2018-06-06
IL300664A (en) 2023-04-01
CN104902876A (zh) 2015-09-09
AR093648A1 (es) 2015-06-17
WO2014085371A1 (en) 2014-06-05
KR102206432B1 (ko) 2021-01-22
EP3400933A1 (en) 2018-11-14
MA38121A1 (fr) 2016-10-31
JP6232443B2 (ja) 2017-11-15
MX2015006867A (es) 2015-10-05
EA028246B1 (ru) 2017-10-31
US20150328320A1 (en) 2015-11-19
CA2891346A1 (en) 2014-06-05
CN107970214A (zh) 2018-05-01
IL266415B2 (en) 2024-03-01
SG11201503688SA (en) 2015-06-29
KR20150091352A (ko) 2015-08-10
UY35157A (es) 2014-06-30
MY170427A (en) 2019-07-31
IN2015DN04094A (ru) 2015-10-09
CN104902876B (zh) 2018-01-19

Similar Documents

Publication Publication Date Title
CY1123376T1 (el) Νεα φαρμακευτικη συνθεση
ZA201406149B (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2015001818A1 (es) Compuestos derivados de azaindol, inhibidores de las proteina quinasas; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer de higado, cancer pancreatico, cancer de pulmon, cancer de mama, leucemias, entre otras.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
UA109464C2 (ru) Спироксиндольные антагонисты mdm2
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
EA201591047A1 (ru) Новая фармацевтическая композиция
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
UY35661A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
PH12014501991B1 (en) Phenicol antibacterials
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
EA201491520A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
HK1217658A1 (zh) 基於吡唑並 嘧啶的化合物、包含其的組合物和其使用方法
PH12015501302A1 (en) Compositions comprising vortioxetine and donepezil
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
EA201790259A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
EA201492173A1 (ru) Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе
CO6781490A2 (es) Nueva composición farmacéutica

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ

PC4A Registration of transfer of a eurasian patent by assignment
PC4A Registration of transfer of a eurasian patent by assignment